ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1291

Efficacy and Safety of Anakinra in Congestive Heart Failure Patients, Including Lvad, with Acute Gouty Arthritis: A Retrospective Study of 36 Patients at an Academic Medical Center

Arash Hassantoufighi1, Paloma Alejandro2, Christopher E. Collins2, Florina Constantinescu2 and Juhi Bhargava3, 1Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, washington, DC, 2Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, 3Internal Medicine, MedStar Washington Hospital Center/Georgetown University Medical Center, washington, DC

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Anakinra and gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Gout is the most common inflammatory arthritis worldwide and many patients with gout are ‘complicated’ by multiple comorbidities including metabolic syndrome, renal disease and congestive heart failure (CHF). Treatment of acute gout can be very challenging sometimes, especially in patients with CHF, including those managed with left ventricular assist devices (LVAD), as there are no guidelines or specific recommendations for the treatment of these patients. Due to concerns of LVAD infection, there is often hesitance to administer systemic corticosteroids, and drugs like NSAIDs are often contraindicated in these patients. Recent data has shown that interleukin (IL)-1 antagonism with anakinra is successful in improving acute gout symptoms in critically ill hospitalized patients with comorbid medical conditions. In this study, we aim to evaluate the efficacy and safety of anakinra for the treatment of acute gouty arthritis in a cohort of hospitalized CHF patients including those with LVAD placement.

Methods:

We conducted a retrospective chart review of all patients who had a diagnosis of CHF and received inpatient anakinra for acute gouty arthritis over a three year period at an academic medical center. Data collected included demographics, use of LVAD, other medication use, and clinical response of gout to treatment. Patient’s records were evaluated for up to a month post anakinra exposure for assessment of gout recurrence and adverse events.

Results:

There were 36 hospitalized gouty patients identified, 6 were monoarticular and 30 polyarticular (26 men; mean age 64 ± 17 years, 10 women; mean age 70 ±13) all of whom carried a CHF diagnosis (median EF 40-45%); 5 patients also had LVAD placement. The mean serum uric acid level was 8.9 (1.9-12.5) and the mean serum creatinine in the non-dialysis patients was 2.1 (0.8-4.8). 2 patients were ESRD and receiving hemodialysis. All patients received anakinra 100mg/d for 3 consecutive days for the management of an acute gouty flare. All patients were also noted to have contraindications to and/or failure of conventional acute gout therapies prior the selection of anakinra. Prior therapies primarily consisted of systemic corticosteroids. Most (35; 97%) patients demonstrated a good response (>50% improvement in pain as charted by the clinician) to anakinra within 3 days, with only one person who failed to demonstrate improvement in gouty arthritis symptoms. During the 1 month post observation period, 3 patients experienced a recurrence of gout flare. There was one death in a non-LVAD patient which was attributed to severe heart failure. There were no infections noted in the charts over a 1 month period of follow up for any patient who received anakinra.

Conclusion:

Anakinra has been shown to be efficacious and safe for the management of acute gouty arthritis, and this study suggests that patients with CHF, including those with LVADs, and acute gout may also be an appropriate candidate population for IL- 1 antagonist therapy. As this was a retrospective chart review, a more accurate assessment of safety and efficacy of anakinra in this group of patients warrants a larger prospective study.


Disclosure: A. Hassantoufighi, None; P. Alejandro, None; C. E. Collins, Exagen Diagnostics,Inc, 2; F. Constantinescu, None; J. Bhargava, None.

To cite this abstract in AMA style:

Hassantoufighi A, Alejandro P, Collins CE, Constantinescu F, Bhargava J. Efficacy and Safety of Anakinra in Congestive Heart Failure Patients, Including Lvad, with Acute Gouty Arthritis: A Retrospective Study of 36 Patients at an Academic Medical Center [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-of-anakinra-in-congestive-heart-failure-patients-including-lvad-with-acute-gouty-arthritis-a-retrospective-study-of-36-patients-at-an-academic-medical-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-anakinra-in-congestive-heart-failure-patients-including-lvad-with-acute-gouty-arthritis-a-retrospective-study-of-36-patients-at-an-academic-medical-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology